A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336

被引:1
作者
Carroll, F. Ivy [1 ]
Kosten, Thomas R. [2 ]
Buda, Jeffrey J. [1 ]
Wang, Laurene [3 ]
Walters, Bradford B. [1 ]
机构
[1] RTI Int, Res Triangle Pk, NC 27709 USA
[2] Baylor Coll Med, Psychiat Neurosci Pharmacol & Immunol & Pathol, Houston, TX 77030 USA
[3] INDApharma, Chapel Hill, NC USA
来源
FRONTIERS IN PHARMACOLOGY | 2018年 / 9卷
关键词
RTI-336; dopamine transporter inhibitor; Clinical Trials; cocaine dependence; addiction and addiction behaviors; pharmacokinetics and drug metabolism (PDM); safety; tolerability; COCAINE USE DISORDER; DOPAMINE TRANSPORTER; NONHUMAN-PRIMATES; SQUIRREL-MONKEYS; RHESUS-MONKEYS; ABUSE; ANALOGS; DRUGS; PHARMACOTHERAPY; INHIBITORS;
D O I
10.3389/fphar.2018.00712
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Preclinical and clinical data suggest that a compound which binds potently to and inhibits the dopamine transporter, but with a slower onset and offset rate than cocaine and with less abuse potential and psychomotor stimulant activity, could be a useful adjunct in the treatment of cocaine dependence. Methods: We assessed the safety, tolerability, and pharmacokinetics (PK) of oral single doses (0.3, 1, 3, 6, 12, and 20 mg) of such an analog, RTI-336, in a randomized, double-blind, and placebo-controlled trial in healthy adult males. Pre-dose and post-dose safety assessments included physical examinations (including neurological examination); orthostatic vital signs; 6-lead continuous electrocardiogram (ECG) telemetry monitoring pre-dose to 8 h post-dose; 12-lead ECGs; clinical chemistry, hematology, and urinalysis; mini mental status examinations; and adverse events. RTI-336 PK was assessed in plasma and urine. Results: 22 participants were enrolled. RTI-336 was well-tolerated up to the maximum evaluated dose of 20 mg. PK analyses demonstrated good absorption with peak plasma maximum concentrations (C-max) occurring around 4 h post-dose and consistent half-lives of around 17 h for the 6, 12, and 20 mg doses. Plasma drug exposure and Cmax increased in proportion to dose. Only 0.02% of RTI-336 excreted was unchanged in urine. Active metabolites UC-M5, UC-M8, and UC-M2 were measurable in plasma and urine, with plasma Cmax of UC-M5 and UC-M8 exceeding that of RTI-336. Three AE possibly were related to RTI-336 and resolved with discontinuation; the one serious AE was unrelated to RTI-336. 2 participants had transient and mild serum total bilirubin elevations (< 1.5 x upper limit of normal) at day 3 post-dose which resolved by day 8 post-dose. Conclusion: All doses including the highest (20 mg) showed excellent safety and tolerability, and further studies in humans are warranted.
引用
收藏
页数:8
相关论文
共 27 条
  • [1] Andry T. N., 2016, EMERGING TREATMENTS
  • [2] [Anonymous], 2015, HHS PUBL
  • [3] BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150
  • [4] Cocaine pharmacology and current pharmacothetherapies for its abuse
    Carrera, MRA
    Meijler, MM
    Janda, KD
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (19) : 5019 - 5030
  • [5] Carroll F. I., 2007, NIDA RES MONOGR, V187, P71
  • [6] Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self-administration after oral administration
    Carroll, F. Ivy
    Fox, Barbara S.
    Kuhar, Michael J.
    Howard, James L.
    Pollard, Gerald T.
    Schenk, Susan
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 553 (1-3) : 149 - 156
  • [7] Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse
    Carroll, FI
    Howard, JL
    Howell, LL
    Fox, BS
    Kuhar, MJ
    [J]. AAPS JOURNAL, 2006, 8 (01) : E196 - E203
  • [8] Pharmacotherapies for treatment of cocaine abuse: Preclinical aspects
    Carroll, FI
    Howell, LL
    Kuhar, MJ
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (15) : 2721 - 2736
  • [9] MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN
    FOLSTEIN, MF
    FOLSTEIN, SE
    MCHUGH, PR
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) : 189 - 198
  • [10] Dextroamphetamine for cocaine-dependence treatment: A double-blind randomized clinical trial
    Grabowski, J
    Rhoades, H
    Schmitz, J
    Stotts, A
    Daruzska, LA
    Creson, D
    Moeller, FG
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (05) : 522 - 526